Develops antibodies for inflammatory and autoimmune diseases.
Dec 2025Revenue $1.54M/yrExpenses $289M/yr
No trendCash runway ≈ 3.0 years from Jun 2026
Figures by year
When will Celldex Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $1.54M and expenses $289M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.54M | $289M | −$287M |
| Dec 2024 | $7.02M | $202M | −$195M |
| Dec 2023 | $6.88M | $161M | −$155M |
| Dec 2022 | $2.36M | $118M | −$115M |
| Dec 2021 | $4.65M | $75.9M | −$71.2M |
| Dec 2020 | $7.42M | $70.8M | −$63.4M |
| Dec 2019 | $3.57M | $58.6M | −$55.0M |
| Dec 2018 | $9.54M | $166M | −$156M |
| Dec 2017 | $12.7M | $134M | −$122M |
| Dec 2016 | $6.79M | $140M | −$133M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.